Hydroxychloroquine (HCQ) may be beneficial for COVID-19 patients, for patients with no cardiac or weight issues, but not for those at risk of cardiovascular disease or pre-existing conditions, states a report in the Journal of Neuroimmune Pharmacology.

HCQ has exhibited efficacy and safety in attenuating COVID-19 associated pneumonia and reduction of viral load. Recent studies found no benefit but more side effects and deaths.

HCQ can control the overproduction of IL-1β and GM-CSF in acute rheumatic fever and reduce IL-6 in patients with rheumatoid arthritis and therefore, may be beneficial for COVID-19 patients via its antioxidant and anti-inflammatory properties. HCQ treatment inhibits glycosylation of ACE2 receptors, preventing binding and cell entry of SARS-CoV-2. However, inhibition of ACE2 generally leads to increases in vasoconstriction and decreases in vasodilation, increasing the chances of inducing or aggravating cardiovascular diseases, posing risks for patients with pre-existing cardiovascular issues, hypertension, and obesity.

HCQ may be beneficial for patients who do not have a history of cardiovascular disease or obesity, but not for patients at risk of cardiovascular disease or older patients with pre-existing conditions.

Univadis will update its Terms of Use and Privacy Policy on January 12, 2016. Please contact privacy@aptushealth.com if you have any questions about these changes. If you continue to use Univadis after January 12, 2016 the new Terms of Use and Privacy Policy will apply. By your continued use of Univadis, you accept and agree to these terms and policies.